756503-71-6Relevant academic research and scientific papers
AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF
-
Page/Page column 57-58, (2021/02/26)
Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode
Meyers, Marvin J.,Pelc, Matthew,Kamtekar, Satwik,Day, Jacqueline,Poda, Gennadiy I.,Hall, Molly K.,Michener, Marshall L.,Reitz, Beverly A.,Mathis, Karl J.,Pierce, Betsy S.,Parikh, Mihir D.,Mischke, Deborah A.,Long, Scott A.,Parlow, John J.,Anderson, David R.,Thorarensen, Atli
scheme or table, p. 1543 - 1547 (2010/06/21)
The work described herein demonstrates the utility of structure-based drug design (SBDD) in shifting the binding mode of an HTS hit from a DFG-in to a DFG-out binding mode resulting in a class of novel potent CSF-1R kinase inhibitors suitable for lead development.
AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS
-
Page 94; 131, (2010/02/08)
Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
